KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Interest & Investment Income (2017 - 2025)

Historic Interest & Investment Income for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to -$62.8 million.

  • Amneal Pharmaceuticals' Interest & Investment Income rose 411.69% to -$62.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$246.5 million, marking a year-over-year increase of 388.53%. This contributed to the annual value of -$258.6 million for FY2024, which is 2277.27% down from last year.
  • As of Q3 2025, Amneal Pharmaceuticals' Interest & Investment Income stood at -$62.8 million, which was up 411.69% from -$65.1 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' 5-year Interest & Investment Income high stood at -$33.3 million for Q1 2022, and its period low was -$65.7 million during Q2 2024.
  • In the last 5 years, Amneal Pharmaceuticals' Interest & Investment Income had a median value of -$50.9 million in 2023 and averaged -$49.9 million.
  • Per our database at Business Quant, Amneal Pharmaceuticals' Interest & Investment Income skyrocketed by 1507.31% in 2021 and then tumbled by 4793.76% in 2023.
  • Over the past 5 years, Amneal Pharmaceuticals' Interest & Investment Income (Quarter) stood at -$34.0 million in 2021, then crashed by 38.49% to -$47.0 million in 2022, then fell by 26.62% to -$59.5 million in 2023, then decreased by 3.55% to -$61.7 million in 2024, then decreased by 1.87% to -$62.8 million in 2025.
  • Its Interest & Investment Income stands at -$62.8 million for Q3 2025, versus -$65.1 million for Q2 2025 and -$56.9 million for Q1 2025.